|
|
基于“热毒理论”论治动脉粥样硬化
|
Abstract:
动脉粥样硬化(atherosclerosis, AS)是由脂质代谢紊乱，在动脉内膜形成斑块导致管腔狭窄的慢性进行性疾病，严重威胁着人类的健康和生命。中医学中认为外邪热毒及内生毒邪，扰乱机体气血运行，长期则影响脏腑功能，致使生理或病理代谢产物不能及时排除，蕴积体内，以致邪气亢盛，败坏形体而化生。故从“热毒理论”探讨动脉粥样硬化的形成与防治。长期研究及临床试验表明清热解毒药能有效治疗动脉粥样硬化。本文选取几味典型的清热解毒草药和方剂，从动脉粥样硬化相关信号通路入手，探讨了栀子、黄芩、四妙勇安汤、黄连解毒汤、泻心汤、葛根芩连汤从减轻氧化应激、减少炎症反应、降脂、稳定斑块、保护血管、抗血栓等方面抑制AS，探讨“热毒理论”防治动脉粥样硬化的可行性，以期提供新的治疗思路。
Atherosclerosis (AS) is a chronic progressive disease caused by lipid metabolism disorders, the formation of plaques in the arterial lining leading to narrowing of the lumen, a serious threat to human health and life. Chinese medicine believes that external heat and toxicity and endogenous toxicity, disturbing the body’s qi and blood operation, long-term impact on the function of internal organs, resulting in physiological or pathological metabolites can not be eliminated in a timely manner, the accumulation of the body, resulting in the evil overgrowth, the corruption of the body and the birth of a new one. Therefore, from the “heat toxicity theory”, explore the formation and prevention of atherosclerosis. Long-term research and clinical trials have shown that heat-clearing and detoxifying medicines are effective in the treatment of atherosclerosis. In this paper, we selected several typical heat and toxin removing herbs and formulas, starting from atherosclerosis related signaling pathway, explored the inhibition of AS by gardenia, scutellariae, Simiao Yong’an Decoction, Huanglian Jie’du Decoction, Xiexin Decoction, Gegeng Qin’lian Decoction from reducing oxidative stress, reducing inflammatory response, lowering lipids, stabilizing plaques, protecting blood vessels, and antithrombotic, etc. This proves the feasibility of preventing atherosclerosis from the “heat toxicity theory”, and provides a new therapeutic idea.
| [1] | 李玉霞, 商瑀家, 宋佳新, 等. 血管平滑肌细胞表型转换与动脉粥样硬化关系的研究进展[J]. 医学研究杂志, 2021, 50(2): 17-19, 27. |
| [2] | 王练妹, 胡继文, 雷卫瑞, 等. 动脉粥样硬化斑块在血流作用下的应力分析[J]. 井冈山大学学报(自然科学版), 2020, 41(1): 16-20. |
| [3] | Ghanem, F.A., et al. (2017) Cholesterol Crystal Embolization Following Plaque Rupture: A Systemic Disease with Unusual Features. Journal of Biomedical Research, 31, 82-94. https://doi.org/10.7555/JBR.31.20160100 |
| [4] | Babaniamansour, P., et al. (2020) The Relation between Atherosclerosis Plaque Composition and Plaque Rupture. Journal of Medical Signals and Sensors, 10, 267-273. |
| [5] | 唐雨墨, 张宝成, 高永翔. 从《灵枢？九宫八风》浅议“虚邪贼风”中的天人相应理论[J]. 中华中医药杂志, 2021, 36(3): 1331-1334. |
| [6] | 王翰飞, 黄羚, 赵岩松. 《温疫论》疫灾环境因素背景探析[J]. 中华中医药杂志, 2022, 37(7): 3687-3692. |
| [7] | 董坤, 张哲. 毒邪致病中医症状探讨[J]. 亚太传统医药, 2019, 15(5): 194-196. |
| [8] | 李彦, 秦璐, 焦一凤, 等. 论七情与上火[J]. 中华中医药杂志, 2017, 32(2): 443-445. |
| [9] | 刘耀岽, 杨逸淦, 柯丽萍. “温邪上受, 首先犯肺, 逆传心包”之辨析[J]. 中国中医基础医学杂志, 2018, 24(2): 155-156. |
| [10] | 周琪, 夏士林, 刘建均, 等. “因毒生热”——毒热理论体系的构建与发展[J]. 中华中医药学刊, 2019, 37(7): 1702-1705. |
| [11] | 招萼华. 论五脏藏神由心主神明发展而来[J]. 中医文献杂志, 2021, 39(1): 37-39, 56. |
| [12] | 白俊杰, 陈子杰, 翟双庆. 白话《黄帝内经》中之“毒”[J]. 西部中医药, 2017, 30(5): 27-29. |
| [13] | 钟霞, 焦华琛, 李运伦. 热毒理论在心系疾病中应用研究进展[J]. 辽宁中医药大学学报, 2020, 22(6): 152-155. |
| [14] | 张惜燕, 邢玉瑞, 胡勇. 中医毒邪研究及相关问题探讨[J]. 陕西中医药大学学报, 2022, 45(1): 48-52. |
| [15] | 张翌蕾, 崔应麟. 毒邪学说研究进展[J]. 中华中医药杂志, 2020, 35(10): 5074-5076. |
| [16] | 李文学. 心血管疾病64例血脂检测分析[J]. 深圳中西医结合杂志, 2016, 26(10): 132-133. |
| [17] | 杨化冰, 邹小娟, 高清华, 等. 代谢性炎症与动脉粥样硬化内生热毒病机探讨[J]. 湖北中医药大学学报, 2019, 21(1): 48-51. |
| [18] | Escós, A., Risco, A. and Cuenda, A. (2016) p38γ and p38δ Mitogen Activated Protein Kinases (MAPKs), New Stars in the MAPK Galaxy. Frontiers in Cell and Developmental Biology, 4, Article 187969. https://doi.org/10.3389/fcell.2016.00031 |
| [19] | Cánovas, B. and Nebreda, A. (2021) Diversity and Versatility of p38 Kinase Signalling in Health and Disease. Nature Reviews Molecular Cell Biology, 22, 346-366. https://doi.org/10.1038/s41580-020-00322-w |
| [20] | Cargnello, M. and Roux, P.P. (2011) Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases. Microbiology and Molecular Biology Reviews, 75, 50-83. https://doi.org/10.1128/MMBR.00031-10 |
| [21] | Prikas, E., Poljak, A. and Ittner, A. (2020) Mapping p38α Mitogen-Activated Protein Kinase Signaling by Proximity-Dependent Labeling. Protein Science, 29, 1196-1210. https://doi.org/10.1002/pro.3854 |
| [22] | Basatemur, G., et al. (2019) Vascular Smooth Muscle Cells in Atherosclerosis. Nature Reviews Cardiology, 16, 727-744. https://doi.org/10.1038/s41569-019-0227-9 |
| [23] | Mielcarska, M., Bossowska-Nowicka, M. and Toka, F. (2021) Cell Surface Expression of Endosomal Toll-Like Receptors—A Necessity or a Superfluous Duplication? Frontiers in Immunology, 11, Article 620972. https://doi.org/10.3389/fimmu.2020.620972 |
| [24] | Duan, T.H., et al. (2022) Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Frontiers in Immunology, 13, Article 812774. https://doi.org/10.3389/fimmu.2022.812774 |
| [25] | Mallenahally Kusha, V., et al. (2018) Toll-Like Receptors: Significance, Ligands, Signaling Pathways, and Functions in Mammals. International Reviews of Immunology, 37, 20-36. https://doi.org/10.1080/08830185.2017.1380200 |
| [26] | El-Zayat, S., Sibaii, H. and Mannaa, F.A. (2019) Toll-Like Receptors Activation, Signaling, and Targeting: An Overview. Bulletin of the National Research Centre, 43, Article No. 187. https://doi.org/10.1186/s42269-019-0227-2 |
| [27] | 陈晶, 赵承梅, 刘刚, 等. TLRs/MyD88信号转导通路的应用研究进展[J]. 继续医学教育, 2019, 33(5): 135-137. |
| [28] | Maik-Rachline, G., Hacohen-Lev-Ran, A. and Seger, R. (2019) Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer. International Journal of Molecular Sciences, 20, Article 1194. https://doi.org/10.3390/ijms20051194 |
| [29] | Engeland, K. (2022) Cell Cycle Regulation: p53-p21-RB Signaling. Cell Death and Differentiation, 29, 946-960. https://doi.org/10.1038/s41418-022-00988-z |
| [30] | Brazzatti, J., et al. (2012) Differential Roles for the p101 and p84 Regulatory Subunits of PI3Kγ in Tumor Growth and Metastasis. Oncogene, 31, 2350-2361. https://doi.org/10.1038/onc.2011.414 |
| [31] | McKenna, M., et al. (2021) Phospho-Form Specific Substrates of Protein Kinase B (AKT1). Frontiers in Bioengineering and Biotechnology, 8, Article 619252. https://doi.org/10.3389/fbioe.2020.619252 |
| [32] | 罗明昊, 胡舒鹏, 王瑞钰, 等. IL-1β通过抑制AKT下调人脐静脉内皮细胞eNOS Ser1177磷酸化水平[J]. 中国病理生理杂志, 2020, 36(10): 1739-1744. |
| [33] | Galstyan, A., et al. (2020) Modulation of the PI3K/mTOR Pathways. In: Kimple, R.J., Ed., Improving the Therapeutic Ratio in Head and Neck Cancer, Academic Press, Cambridge, 89-105. https://doi.org/10.1016/B978-0-12-817868-3.00005-6 |
| [34] | Lu, Y.B., Shi, C., Yang, B., Lu, Z.F., Wu, Y.L., Zhang, R.Y., He, X., Li, L.M., Hu, B., Hu, Y.W., Zheng, L. and Wang, Q. (2020) Long Noncoding RNA ZNF800 Suppresses Proliferation and Migration of Vascular Smooth Muscle Cells by Upregulating PTEN and Inhibiting AKT/mTOR/HIF-1α Signaling. Atherosclerosis, 312, 43-53. https://doi.org/10.1016/j.atherosclerosis.2020.09.007 |
| [35] | 赵晶, 秦合伟, 李彦杰, 等. 血管软化丸调控PI3K/Akt/mTOR通路影响细胞自噬及抗动脉粥样硬化的作用机制研究[J]. 中华中医药学刊, 2020, 38(1): 65-69, 268-270. |
| [36] | Tang, F. and Yang, T.L. (2018) MicroRNA-126 Alleviates Endothelial Cells Injury in Atherosclerosis by Restoring Autophagic Flux via Inhibiting of PI3K/Akt/mTOR Pathway. Biochemical and Biophysical Research Communications, 495, 1482-1489. https://doi.org/10.1016/j.bbrc.2017.12.001 |
| [37] | Xiong, Q.P., et al. (2020) A Sulfated Polysaccharide from the Edible Flesh of Cipangopaludina chinensis Inhibits Angiogenesis to Enhance Atherosclerotic Plaque Stability. Journal of Functional Foods, 66, Article ID: 103800. https://doi.org/10.1016/j.jff.2020.103800 |
| [38] | Osaki, L., and Gama, P. (2013) MAPKs and Signal Transduction in the Control of Gastrointestinal Epithelial Cell Proliferation and Differentiation. International Journal of Molecular Sciences, 14, 10143-10161. https://doi.org/10.3390/ijms140510143 |
| [39] | 史雨晨, 柳景华. 成纤维细胞生长因子21与心血管疾病关系的研究进展[J]. 中国医药, 2018, 13(9): 1430-1433. |
| [40] | 郑一, 郭鹤, 包永睿, 等. 基于NF-κB/NLRP3/Caspase-1通路介导的巨噬细胞焦亡探究葛根芩连汤对动脉粥样硬化易损斑块的干预机制[J]. 中国实验方剂学杂志, 2022, 28(11): 70-78. https://doi.org/10.13422/j.cnki.syfjx.20220611 |
| [41] | 刘聃, 刘凤英, 黄颖, 等. 栀子中栀子苷的研究进展[J]. 农产品加工, 2021(12): 72-75. https://doi.org/10.16693/j.cnki.1671-9646(X).2021.12.017 |
| [42] | 沈迪. 栀子苷抑制巨噬源性泡沫细胞形成的机制研究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2020. https://doi.org/10.27674/d.cnki.gcyku.2020.001503 |
| [43] | 王复婧, 黄小飞, 赵丹丹, 苏志杰, 程赛博, 徐煜凌, 孙学刚, 贾钰华, 周凤华. 栀子苷通过PI3K通路抑制OX-LDL诱导HUVEC中KLF2表达[J]. 中药药理与临床, 2018, 34(1): 53-56. https://doi.org/10.13412/j.cnki.zyyl.2018.01.013 |
| [44] | Jin, Z., Li, J., Pi, J., Chu, Q., Wei, W., Du, Z., Qing, L., Zhao, X. and Wu, W. (2020) Geniposide Alleviates Atherosclerosis by Regulating Macrophage Polarization via the FOS/MAPK Signaling Pathway. Biomedicine & Pharmacotherapy, 125, Article ID: 110015. https://doi.org/10.1016/j.biopha.2020.110015 |
| [45] | 薛亚, 朱为康, 李雁, 等. 《伤寒论》中黄芩的本草考证[J]. 上海中医药杂志, 2021, 55(5): 33-37. https://doi.org/10.16305/j.1007-1334.2021.2008048 |
| [46] | Zhang, X., Qin, Y., Ruan, W., Wan, X., Lv, C., He, L., Lu, L. and Guo, X. (2021) Targeting Inflammation-Associated AMPK//Mfn-2/MAPKs Signaling Pathways by Baicalein Exerts Anti-Atherosclerotic Action. Phytotherapy Research, 35, 4442-4455. https://doi.org/10.1002/ptr.7149 |
| [47] | 周科, 潘俊峰, 龙斌斌, 等. 四妙勇安汤治疗血栓闭塞性脉管炎的疗效观察[J]. 中国医院用药评价与分析, 2018, 18(5): 592-594. https://doi.org/10.14009/j.issn.1672-2124.2018.05.006 |
| [48] | 于红红, 吴玛莉, 张智伟, 等. 四妙勇安汤含药血清对巨噬细胞TLR4/MyD88信号通路及其下游炎症因子的影响[J]. 免疫学杂志, 2016, 32(6): 519-522. https://doi.org/10.13431/j.cnki.immunol.j.20160101 |
| [49] | 于红红, 李芳, 罗瑞熙, 等. 四妙勇安汤含药血清对LPS诱导的M1/M2巨噬细胞极化及NF-κB/NLRP3通路的影响[J]. 免疫学杂志, 2023, 39(4): 320-325. https://doi.org/10.13431/j.cnki.immunol.j.20230041 |
| [50] | 于宁, 宋囡, 王莹, 等. 四妙勇安汤抑制焦亡通路TLR4/NLRP3/Caspase-1防治动脉粥样硬化机制研究[J]. 中华中医药学刊, 2021, 39(8): 199-203, 279. https://doi.org/10.13193/j.issn.1673-7717.2021.08.048 |
| [51] | 葛其卉. 从Nrf2/Trx1/TXNIP通路研究活血解毒法调节动脉粥样硬化小鼠炎症体活化介导炎症的机制[D]: [硕士学位论文]. 天津: 天津中医药大学, 2021. https://doi.org/10.27368/d.cnki.gtzyy.2021.000056 |
| [52] | 杜雅薇, 吴圣贤. 解毒活血法对动脉粥样硬化斑块IκK-β/IκB-α/NF-κB信号通路的影响[J]. 中华中医药学刊, 2013, 31(5): 999-1001, 1220. https://doi.org/10.13193/j.archtcm.2013.05.41.duyw.048 |
| [53] | 姜月平, 魏春华. 黄连解毒汤主要有效成分的理化性质研究[J]. 北方药学, 2017, 14(1): 7. |
| [54] | 郭重仪. 黄连解毒汤对动脉粥样硬化大鼠MCP-1/CCR2通路mRNA表达的干预作用[J]. 海峡药学, 2010, 22(2): 30-32. |
| [55] | 于红红, 俞琦, 盛蒙, 等. 黄连解毒汤含药血清对ox-LDL诱导的巨噬细胞泡沫化TLR7信号通路的影响[J]. 中国免疫学杂志, 2020, 36(17): 2082-2085. |
| [56] | 罗舒文, 何金涛, 王腊, 等. 基于PPARγ/NF-κB通路探讨黄连解毒汤干预M1/M2极化延缓AS的作用机制[J]. 时珍国医国药, 2022, 33(9): 2065-2069. |
| [57] | 刘婷, 于红红, 王文佳, 等. 基于PPARγ/LXRα/ABCG1通路探讨黄连解毒汤对泡沫细胞脂质蓄积的干预作用[J]. 时珍国医国药, 2023, 34(4): 838-842. |
| [58] | 冯云舒. 泻心汤类方应用研究概况[J]. 亚太传统医药, 2016, 12(5): 64-65. |
| [59] | 于红红, 俞琦, 蔡琨, 等. 泻心汤含药血清对RAW264.7源性泡沫细胞TLR9/MyD88/NF-κB p65信号通路的影响[J]. 中国实验方剂学杂志, 2019, 25(18): 24-29. https://doi.org/10.13422/j.cnki.syfjx.20191836 |
| [60] | 黄鑫磊, 贾雪雯, 丁元庆. 葛根芩连汤临床应用进展[J]. 山东中医药大学学报, 2020, 44(2): 215-220. https://doi.org/10.16294/j.cnki.1007-659x.2020.02.020 |
